Omicron’s experimental enhancement of Moderna generates high levels of antibodies that neutralize the BA.4 and BA.5 subvariants, according to preliminary clinical trial data.
Key points:
- Omicron BA.4 and BA.5 subvariants are becoming the dominant forms of COVID-19 in Australia and abroad
- New data from Moderna show that an updated reinforcement adapted to Omicron generates high levels of antibodies against BA.4 and BA.5
- Moderna’s medical director says new reinforcement awaits approval in Australia in August
These sub-variants have been consolidated in the US and Australia and are already driving a new wave of infections in the UK.
Moderna’s results, which have not been peer-reviewed, are based on an announcement earlier this month that people receiving the new booster were producing more anti-Omicron antibodies in general than if they were receiving a fourth dose. of the original vaccine.
Paul Burton, medical director of Moderna, said the test participants’ antibody levels were high enough to provide “good clinical protection” against BA.4 and BA.5.
“We know that an antibody level of about 400 units … offers very good clinical protection against COVID infection and, without a doubt, against more serious illnesses, hospitalization and death,” he said.
Of the 437 adults who had the specific Omicron booster, those who had not yet had COVID generated mean levels of neutralizing antibodies of BA.4 and BA.5 of 727 units after one month.
People who had a previous COVID infection saw a massive jump in BA.4 and BA.5 neutralizing antibodies: more than 2,700 units.
“Very high [antibody] levels, I would say, [are] It is guaranteed to correlate with clinical protection against infection and serious illness, and … I think these levels will also provide good long-term protection, “said Dr. Burton.
Participants are being tracked to see if they may be infected with COVID and when.
University of Queensland infectious disease physician and clinical microbiologist Paul Griffin said neutralizing antibody responses was a good substitute for protection, but seeing how reinforcement worked in the real world was the most important thing.
“Obviously, this takes more time to accumulate this data, so this is a useful first step, but then clinical trials will follow that we hope will show effectiveness in people.”
A two-in-one COVID vaccine
The updated Moderna reinforcement, called mRNA-1273,214, was developed in January, when Omicron was sweeping Australia.
The dam contains instructions in the form of mRNA for your body to build up-to-date proteins, bumps that the virus uses to infect our cells.
Your immune system then makes antibodies against various parts of the ear protein. If these antibodies rediscover spike proteins in the form of a real virus, they will recognize it and catch it.
And if they stick to the end of the ear, which is the part that sticks to our cells, they neutralize it.
But if the ear protein changes too much, especially its captivating end, this neutralizing power falls.
To avoid this, Moderna’s new reinforcement has mRNA instructions for the two-ear spike protein: the ancestral SARS-CoV-2 virus that originated in Wuhan, plus the subvariant Omicron BA.1, which circulated in the January
In the following months, other Omicron subvariants split, with BA.4 and BA.5 now beginning to dominate new infections in many parts of the world.
Loading
BA.4 and BA.5 have the same series of genetic mutations in their spike protein, slightly changing their shape and allowing them to pass under the radar of the immune system and evade some of the antibodies we may have produced against others. variants, including antibodies. produced during BA.1 infection.
So how can a vaccine against two viruses, the original and Omicron BA.1, produce antibodies that neutralize a lot of others?
This is a phenomenon called “epitope enlargement,” Dr. Burton said, which Moderna saw in trials of another variant-specific enhancement that included mRNA for the ancestral virus and Beta variants.
More information on vaccine release:
“When you put two mRNAs together and two slightly different versions of the spike protein come into your body … you don’t just get antibodies against what you’re putting in. You get this very wide coverage of all kinds. Of possible new variants.
“If you now have Wuhan and Omicron, which is so far from the original Wuhan, then join them [in an mRNA vaccine]you can get very high levels of antibodies produced against BA.1, BA.2, BA.4 and 5, plus Delta and Beta and everything else. “
This, according to RMIT University professor of immunology Magdalena Plebanski, is “very good news”.
Omicron is not the latest variant of COVID, and previous variants could reappear on the track.
“[The booster] it’s not just tackling a new strain and then losing power against previous strains, ”Professor Plebanski said.
“The fact that it now offers similar protection against the ancestral strain means that at least we have it covered as well.”
For the American and European autumn … and the Australian winter?
Moderna is submitting clinical trial data to an academic journal and is looking to deploy the updated reinforcement for the northern hemisphere fall.
By then, BA.4 and BA.5 “will probably be a distant memory,” but the new reinforcement will cover variants that have not yet emerged, Dr. Burton said.
“Our goal is also to be able to support Australia and its winter and try, with the support of TGA and ATAGI, to provide this vaccine booster candidate in Australia, even in August.”
Moderna is one of the few companies and research institutes that are testing Omicron-specific vaccines. (ABC News: Cameron Schwarz)
The updated Modern photo is a reasonable reinforcement option, Professor Plebanski said.
“And time is of the essence. At some point, our immunity [generated from third or fourth doses of COVID vaccine] will decrease “.
Hello in your inbox
Get the latest ABC news and health information.
Dr. Griffin agreed. Variant-specific reinforcements are the way to go, he said, and will be adjusted as needed, such as the seasonal flu vaccine.
“But it won’t be as easy as some people might think right now, because we really need to think about the best time to use it. [a booster]”He said.
The message of why specific reinforcements of variants are needed should also be considered to ensure sufficient and timely absorption of the reinforcement, Dr. Griffin added.
“It’s okay to develop it, but if we don’t do it quickly, it can be redundant.
“And if the absorption is not high enough, it will not have the impact we need.”
Loading form …